Navigation Links
Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
Date:5/8/2008

Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI

Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy

HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio-engineered R stent, the world's first pro-healing stent, will be presented next week in a symposium at EuroPCR 2008 in Barcelona, Spain.

The symposium, titled "Clinical Impact of the Pro-Healing Stent," will take place at noon on May 15. Germano Di Sciascio, M.D., professor and chairman of cardiology at Campus Biomedico, University of Rome, Italy, will serve as the chairperson of the symposium and will present 14 month follow up data on 78 patients treated with the Genous stent.

Jonathan Hill, M.D., of King's College, London, will discuss the functional importance of endothelial progenitor cells for accelerated natural healing. Huay-Cheem Tan, M.D., National University Hospital, Singapore will present on the use of the Genous Bio-engineered R stent in acute myocardial infarction patients and Michael Kutryk, M.D., Ph.D. of St. Michael's Hospital, Toronto will focus on the use of the stent in patients who cannot tolerate dual-antiplatelet therapy.

Robbert de Winter, M.D., Ph.D., director of the catheterization laboratory at the Academic Medical Center, Amsterdam, will show the 12 month follow-up data from a 193-patient, single-center, prospective, single blind study called TRIAS HR Pilot with the Genous stent randomized with a drug eluting stent. In addition, de Winter will include interim follow up data from patient subsets in e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients. Dr de Winter is the principal investigator of the TRIAS HR Pilot study and co-principal investigator of the e-HEALING registry.

"We expect the data to strengthen our conviction that Gen
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...re/ -- There are a record 301,new medicines being ...,report released here today during a briefing that...lnesses have on patients, their families,and soci...million American,adults. The briefing, led by the ...ca (PhRMA), featured Emmy Award-winning actor Joey...
(Date:7/24/2008)...e body temperature, for home,and clinical use, WE...z-Med, Inc.,(subsidiary of American Scientific Res...ributor of the Thermofocus(R) 5-in-1 non-contact,t...a clinical study,conducted by the Second Children,...ly, which proves that the Thermofocus(R) measures ...
(Date:7/23/2008)...apy to Treat the Disease -, WAYNE, N.J. and EMERY...ayer HealthCare Pharmaceuticals and Onyx Pharmaceu...he New England Journal of Medicine published,resul...) (sorafenib),tablets decreased the absolute risk ...le hepatocellular carcinoma (HCC), or liver cancer...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Some Epilepsy Patients Are Good Candidates for Surgery 183 1Some Epilepsy Patients Are Good Candidates for Surgery 183 2GERD Not Limited to Grownups 181 1GERD Not Limited to Grownups 181 2GERD Not Limited to Grownups 181 3Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 1Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 2Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 3Social parasites of the smaller kind 150 1Social parasites of the smaller kind 150 2
...lo., June 11, 2007 /PRNewswire/ -- Accera, Inc.,to...n of its Phase,IIb clinical trial of AC-1202 (Keta...s Association,s International Conference on,Preven...th the,findings of earlier clinical and preclinica...nificantly improve the memory and,cognition of sub...
....--(BUSINESS WIRE)--Jun 12, 2007 - Critical,Therap...blication,of data from a pivotal Phase III clinica...e tablets in the June 2007 issue of the,Journal of...d Drug,Administration (FDA) on May 30, 2007. Criti...artner Dey, L.P. (DEY), expects to,begin marketing...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Famil...cancer treatment solutions at the 2008,American As...meeting,demonstrating how the joint forces of Ele...iation therapy planning and delivery solutions tha...ter experience for,patients, as well as enhance cl...
(Date:7/25/2008)...urday can be toughest for those trying to drop pou...althDay News) -- Anyone who has avoided Monday mor...nds are not a dieter,s friend. , Now, researche...s about weekends being their undoing: Most people ...ng to lose weight. , "Weekend indulgences can w...
(Date:7/25/2008)... The Drug Information Associ...FDA) will host the Critical Path Initiative (CPI) ...r 15 -16; Bethesda, MD) and the Critical Path Tran.... , Horsham, PA (PRWEB) J... Information Association (DIA)] and the Food and D...
(Date:7/24/2008)... Hoag to lease hospital faci... Newport Beach, CA (Vocus) July 24, 2008 -- Hoa...reement with HCP, Inc. (NYSE: HCP), a Real Estate ...to lease its 175-bed hospital facility on Sand Can..., , , ,The facility is currently operated by Tene...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2
...esperate to stun people with the way she looks, fo....3 kilograms in one month . The 26-year-old is on ...by her celeb trainer Harley Pasternak, and she eve...e nutritional meals delivered to her doorstep. Sim...
...ted that circumcision 'significantly' cuts HIV ris...ess important as a deterrent to the global AIDS pa...bott who conducted statistical empirical research ...the world conducted the study. He found that the n...
...stitute have found in animal models just how great...celerating breast cancer . Until this study, the s...east cancer had not been clearly established, and ...dings could lead to a better understanding of the ...
...red an inquiry into the alleged incident of a 15-y...on, an official said Thursday. In April, Dileepa...ction operation under his parents' supervision at ...spital in Manapparai, about 450 km from the state ...
Other Medicine News:Health News:Male Circumcision Overstated as Deterrent to Global AIDS Pandemic 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3
...iagnostic collection software. Sandman Elite versi...collection software offers customizable digital fi...post recording. The scoring displays a list of sco...ing current number of events, frequency and averag...
...ur SleepWorks software and Hyppo headbox. XLTEK's ...ostic sleep-testing needs. It's compliant, accurat...ked up by 24/7 support provided by a team of knowl...t, you can expand your capabilities to include cli...
... in the Beehive product line, combines decades of ...ogy of the 21st century. Beehive Millennium is a p..., providing complete data acquisition, recording a...ilepsy monitoring applications. Beehive Millennium...
...ged unit capable of handling a wide range of stimu... research laboratories. The built-in isolation cir...s artifacts. The twin pulse circuit makes this sti...n Signal Marker For those investigators requiring ...
Medicine Products: